Observational study shows improved postpartum outcomes in women with multiple sclerosis using natalizumab during pregnancy, indicating a viable treatment approach.
Continuing natalizumab treatment until late pregnancy was associated with better postpartum clinical and radiological outcomes. Neonatal anthropometric measures were comparable to reference child growth standards. These findings support that late pregnancy natalizumab continuation may be a viable high efficacy strategy for women with highly active MS.
No takes yet. Share an insight, caveat, or question.
Kitsos et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: